The 2022 IAS-USA Guidelines Virtual Update: Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Last Modified: Jun 5, 2023 @ 11:14 AM

Program Description

This course will review the newly released Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel, published online by JAMA on December 1, 2022. This course will cover the key changes and updates through a novel series of presentations and interactive panel sessions presented by the experts who served on the guidelines panel. The 2022 guidelines include updated recommendations on initiating and changing antiretroviral therapy and prevention of HIV infection. New sections include recommendations for substance use disorder and mpox.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Describe the latest recommendations for managing HIV in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Initiate and monitor HIV prevention intervention strategies using the latest recommendations, including the use of postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
• Describe the most current data on currently available and newly available antiretroviral drugs and approaches
• Describe the current best understanding of the impact of COVID-19 on HIV
• Describe the current best understanding of the impact of mpox on HIV
• Describe the current best understanding of the impact of substance use disorder on HIV

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.